PS
CORT icon

Principal Securities’s Corcept Therapeutics CORT Stock Holding History

Principal Securities’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,354
Closed -$113K – 1764
2025
Q3 		$113K Sell
1,354
-578
-30% -$41.8K ﹤0.01% 1544
2025
Q2 		$142K Buy
1,932
+689
+55% +$50K ﹤0.01% 1384
2025
Q1 		$62.6K Hold
1,243
– – ﹤0.01% 1662
2024
Q4 		$62.6K Buy
1,243
+483
+64% +$25.3K ﹤0.01% 1661
2024
Q3 		$35.2K Buy
760
+393
+107% +$14K ﹤0.01% 1846
2024
Q2 		$11.9K Buy
367
+32
+10% +$877 ﹤0.01% 2315
2024
Q1 		$8.44K Sell
335
-21
-6% -$496 ﹤0.01% 2421
2023
Q4 		$11.6K Buy
+356
New +$9.78K ﹤0.01% 2165

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Principal Securities's CORT Position: Q4 2025 in Review

Principal Securities sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 1,354 shares — an estimated $113K sold.

Principal Securities first reported a position in CORT in Q4 2023 and held it in 8 quarters. The position peaked at $142K in Q2 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Principal Securities reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 1,354 Corcept Therapeutics shares in Q4 2025, an estimated $113K.
  • Principal Securities first reported a position in Corcept Therapeutics in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Corcept Therapeutics position peaked at $142K in Q2 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.